Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cirtuvivint - Biosplice Therapeutics

Drug Profile

Cirtuvivint - Biosplice Therapeutics

Alternative Names: SM-08502

Latest Information Update: 18 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samumed
  • Developer Biosplice Therapeutics
  • Class Amides; Antineoplastics; Isoquinolines; Piperazines; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action DYRK kinase inhibitors; Wnt signalling pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 09 Sep 2022 Preliminary pharmacokinetics, pharmacodynamics, safety and efficacy data from phase I and Ib trial in Solid tumors presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 08 Apr 2022 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research 2022 (AACR-2022)
  • 27 Jan 2022 Biosplice Therapeutics and Epic Sciences enters into a clinical trial collaboration for Cirtuvivint for Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top